Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Fairbanks Capital Management Inc.

Fairbanks Capital Management Inc. grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,112 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,178 shares during the quarter. Jazz Pharmaceuticals comprises approximately 1.9% of Fairbanks Capital Management Inc.’s portfolio, making the stock its 18th biggest position. Fairbanks Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $2,894,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after acquiring an additional 99 shares in the last quarter. ProShare Advisors LLC raised its position in Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after acquiring an additional 105 shares in the last quarter. Ontario Teachers Pension Plan Board raised its position in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after acquiring an additional 108 shares in the last quarter. Pinnacle Associates Ltd. raised its position in Jazz Pharmaceuticals by 1.1% in the first quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after acquiring an additional 110 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Piper Sandler cut their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Finally, UBS Group dropped their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Trading Down 1.2 %

Jazz Pharmaceuticals stock opened at $107.14 on Monday. The stock has a market cap of $6.62 billion, a PE ratio of 22.09, a P/E/G ratio of 1.34 and a beta of 0.57. The stock has a 50-day moving average price of $109.75 and a 200 day moving average price of $112.12. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.